RecruitingPHASE2, PHASE3NCT06841679

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Studying Catastrophic antiphospholipid syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Intervention
Utidelone Capsule(drug)
Enrollment
778 enrolled
Eligibility
18 years · All sexes
Timeline
20252030

Study locations (10)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06841679 on ClinicalTrials.gov

Other trials for Catastrophic antiphospholipid syndrome

Additional recruiting or active studies for the same condition.

See all trials for Catastrophic antiphospholipid syndrome

← Back to all trials